9.2K(top 0.1%)
PR articles
500.0K(top 0.1%)
PR citations
275(top 0.1%)
PR h-index
309(top 0.1%)
h-index
11.0K
documents
685.1K
doc citations
13.1K
citing journals

Top Articles

#TitleJournalYearCitations
1Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018Cell Death and Differentiation20185,236
2Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell20174,390
3Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)Autophagy20164,122
4The future of immune checkpoint therapyScience20153,731
5Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine20043,269
6One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology20083,083
7Guidelines for the use and interpretation of assays for monitoring autophagyAutophagy20122,657
8Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology20172,570
9First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialLancet, The20212,400
10Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1Autophagy20212,191
11Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology20082,101
12B cells and tertiary lymphoid structures promote immunotherapy responseNature20202,077
13A Landscape of Driver Mutations in MelanomaCell20121,893
14Lung CancerNew England Journal of Medicine20081,888
15Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative PotentialCell20151,773
16Tumor and Microenvironment Evolution during Immunotherapy with NivolumabCell20171,707
17The Human Cell AtlasELife01,516
18B cells are associated with survival and immunotherapy response in sarcomaNature20201,477
19Pancreatic cancerLancet, The20041,422
20Eicosanoids and cancerNature Reviews Cancer20101,374
21Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptideNature20071,354
22Hallmarks of response, resistance, and toxicity to immune checkpoint blockadeCell20211,331
23Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinomaJournal of Hepatology20221,309
24STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung AdenocarcinomaCancer Discovery20181,304
25Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline ChemotherapyCancer Cell20141,281
26Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialLancet Oncology, The20171,277
27Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyJournal of Clinical Oncology20071,244
28PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell20041,222
29Loss of PTEN Promotes Resistance to T Cell–Mediated ImmunotherapyCancer Discovery20161,209
30Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2Journal of Clinical Oncology20041,151
31The role of ferroptosis in ionizing radiation-induced cell death and tumor suppressionCell Research20201,073
32Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response CriteriaJournal of Clinical Oncology20071,069
33Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 TherapyCell20161,049
34Physical limits of cell migration: Control by ECM space and nuclear deformation and tuning by proteolysis and traction forceJournal of Cell Biology20131,048
35Association analysis identifies 65 new breast cancer risk lociNature20171,044
36A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeCell20181,032
37Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell20171,014
38Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialLancet, The2019986
39NASH limits anti-tumour surveillance in immunotherapy-treated HCCNature2021975
40Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant ChemotherapyJournal of Clinical Oncology1999969
41Immune checkpoint therapy—current perspectives and future directionsCell2023954
42ESR1 ligand-binding domain mutations in hormone-resistant breast cancerNature Genetics2013927
43ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-upAnnals of Oncology2016922
44Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine1990890
45Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyLancet Oncology, The2020881
46State-of-the-art strategies for targeting the DNA damage response in cancerNature Reviews Clinical Oncology2018875
47Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyLancet Oncology, The2016848
48The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineOncologist2009836
49High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer typesAnnals of Oncology2021818
50Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast CancerJournal of Clinical Oncology2005812